Mark Bieda

Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer

Lauren Farr, E. Trueblood, S. Sandall, 2022, Cancer Research.